Advertisement

Topics

PubMed Journals Articles About "Pharma Shkreli Convicted Securities Fraud Trial" RSS

07:16 EDT 26th September 2018 | BioPortfolio

Pharma Shkreli Convicted Securities Fraud Trial PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Pharma Shkreli Convicted Securities Fraud Trial articles that have been published worldwide.

More Information about "Pharma Shkreli Convicted Securities Fraud Trial" on BioPortfolio

We have published hundreds of Pharma Shkreli Convicted Securities Fraud Trial news stories on BioPortfolio along with dozens of Pharma Shkreli Convicted Securities Fraud Trial Clinical Trials and PubMed Articles about Pharma Shkreli Convicted Securities Fraud Trial for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pharma Shkreli Convicted Securities Fraud Trial Companies in our database. You can also find out about relevant Pharma Shkreli Convicted Securities Fraud Trial Drugs and Medications on this site too.

Showing "Pharma Shkreli Convicted Securities Fraud Trial" PubMed Articles 1–25 of 4,400+

FraudBuster: Reducing Fraud in an Auto Insurance Market.

Nonstandard insurers suffer from a peculiar variant of fraud wherein an overwhelming majority of claims have the semblance of fraud. We show that state-of-the-art fraud detection performs poorly when deployed at underwriting. Our proposed framework "FraudBuster" represents a new paradigm in predicting segments of fraud at underwriting in an interpretable and regulation compliant manner. We show that the most actionable and generalizable profile of fraud is represented by market segments with high confidence...


District nurses and NHS fraud.

Two cases of fraud by district nurses demonstrate that district nurses need to be familiar with the behaviour that amounts to fraudulent activity, so they are able to protect NHS assets and take appropriate action to minimise the loss of funds needed for patient care and treatment. Fraud costs the NHS billions of pounds each year and takes money away from front-line services. The Fraud Act 2006 has made the offence clearer and easier to prosecute. Offences can range from false representation about qualifica...

Food fraud and the perceived integrity of European food imports into China.

Persistent incidents of food fraud in China have resulted in low levels of consumer trust in the authenticity and safety of food that is domestically produced. We examined the relationship between the concerns of Chinese consumers regarding food fraud, and the role that demonstrating authenticity may play in relieving those concerns.


Depression in the wives of convicted men: prevalence and associated factors.

To estimate the prevalence of depression and to identify the main risk factors associated with depression in wives of convicted men.

Economically Motivated Food Fraud and Adulteration in Brazil: Incidents and Alternatives to Minimize Occurrence.

Brazil is one of the world's largest food producers. Adulteration of foods is often reported and represent an important potential threat to food safety. Because of this, reduction of the vulnerability of foods to adulteration is of high priority to Brazil. This study analyzes economically motivated food fraud and adulterations in Brazil between 2007 and 2017, based on academic journal reports. In addition, alternatives are proposed to minimize these incidents through good practices, traceability systems and...

A guide to manufacturing CAR T cell therapies.

In recent years, chimeric antigen receptor (CAR) modified T cells have been used as a treatment for haematological malignancies in several phase I and II trials and with Kymriah of Novartis and Yescarta of KITE Pharma, the first CAR T cell therapy products have been approved. Promising clinical outcomes have yet been tempered by the fact that many therapies may be prohibitively expensive to manufacture. The process is not yet defined, far from being standardised and often requires extensive manual handling ...

Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence.

Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence.

Generative adversarial network based telecom fraud detection at the receiving bank.

Recently telecom fraud has become a serious problem especially in developing countries such as China. At present, it can be very difficult to coordinate different agencies to prevent fraud completely. In this paper we study how to detect large transfers that are sent from victims deceived by fraudsters at the receiving bank. We propose a new generative adversarial network (GAN) based model to calculate for each large transfer a probability that it is fraudulent, such that the bank can take appropriate measu...

Clinical trials go virtual, big pharma dives in.

Recent Developments and Digital Perspectives in Food Safety and Authenticity.

Food Safety is of fundamental importance for the food processing industry, food retailers and distributors, as well as for the competent authorities because of its potentially direct impact on consumers' health. Next to the prevention of microbiological, chemical, and physical hazards increasing efforts are currently made to combat risks associated with food fraud or food authenticity. Food Safety Management Systems nowadays comprise food safety, food defense, and food fraud prevention measures trying to co...

21 Century Citizen Pharma: The FDA & Patient-Focused Product Development.

Perpetual debate regarding the delicate balance between access and innovation and the protection of the public health and safety dominate discussions of the United States Food and Drug Administration ("FDA"). Established chiefly as a command and control federal administrative agency, iterative changes in legislation have shaped the FDA's activity in drug, biologic, and medical device regulation over the course of the last one hundred plus years. The most recent fundamental reframing of the agency's authorit...

Ethical aspects in medical publishing in Belgium.

Medical publishing has become a pivotal aspect of all stages of career development in medicine in Belgium. Publication pressure is therefore present from the stage of the medical student to the level of the head of an academic medical service. This pressure represents a real danger to commit scientific misconduct, ranging from minor missteps to severe fraud. Recent surveys have shown that scientific misconduct and publication fraud represent an important problem in medical publishing, more than in other sci...

Pharmacogenomics and the Placebo Response.

There is perhaps no more important time in the history of placebos to consider their role in clinical trials and in medicine. Increasingly well-designed pharmaceutical and academic clinical trials testing promising and established drug and surgical interventions have failed to "beat" the placebo response. The collateral damage resulting from these failures is staggering; novel treatments, many with compelling mechanisms of action and promising Phase 2 trial results, never reach the patient, adversely affect...

Adaptive and Platform Trials in Remote Damage Control Resuscitation.

The traditional approach to clinical trial design requires assuming precise values for multiple unknown parameters, resulting is a trial design that is unlikely to perform well if one or more of those assumptions turn out to be incorrect. During conduct of the trial, trial characteristics are often held fixed, even if incoming data suggest that one or more design assumptions were incorrect. This leads to an increased risk of a failed trial. In contrast, an adaptive clinical trial is designed to take advanta...

Differences in child sexual abuse cases involving child versus adolescent complainants.

While adolescents report the highest rates of sexual abuse victimization, few studies have investigated how child sexual abuse (CSA) cases involving adolescent complainants may differ from cases involving child complainants. The current study draws on 3,430 allegations of CSA in Canada to compare abuse characteristics and judicial outcomes in cases involving adolescent complainants to cases involving child complainants. Adolescent complainants were more likely than child complainants to be abused by a stran...

Real-World Evidence in the Real World: Beyond the FDA.

The 21 Century Cures Act ("Cures Act") relies on the concept of real-world evidence ("RWE") to improve the Food and Drug Administration ("FDA") approval process. This has amplified interest and furthered momentum in applying RWE more broadly, beyond FDA regulation. In this article, we discuss the understandable appeal of RWE's pragmatic application and its many potential benefits. But we also caution that claims about RWE's wide-ranging, ameliorative impact on the health care system are likely overstated....

The meteoric rise and dramatic fall of Theranos: lessons learned for the diagnostic industry.

In this piece we discuss and reflect on the conclusion of the Theranos saga in the light of its fraud conviction. Theranos (founded in 2003 by Elizabeth Holmes) was supposed to disrupt the diagnostic testing industry by developing technology which could perform dozens of tests using a tiny amount of blood from a finger-prick. As a result, Ms. Holmes rose to fame, becoming the world's youngest female self-made billionaire and was plastered across magazine covers. However, in 2014, Theranos began to fall apar...

The Common Pharmaceutical Market of the Eurasian Economic Union: A Regulatory Review.

According to the Treaty on the Eurasian Economic Union, a common pharmaceutical market was supposed to become operational on January 1, 2016. Nevertheless, the responsible parties did not meet the deadline. Although a majority of the draft guidelines regulating this process were already known in 2014 and 2015, the anticipated process itself caused anxiety among representatives of the foreign pharma industry, who tried to prepare for coming challenges. Among other possible issues, the ambiguity of transition...

A sequential trial effect based on the motor interference effect from dangerous objects: An ERP study.

This study aims to investigate whether processing a prepared response toward a dangerous object in a previous trial influences subsequent trial processing.

A Randomized Clinical Trial of n-of-1 Trials-Tribulations of a Trial.

Multicenter Randomized Controlled Crossover Trial Comparing Hemodynamic Optimization Against Echocardiographic Optimization of AV and VV Delay of Cardiac Resynchronization Therapy: The BRAVO Trial.

BRAVO (British Randomized Controlled Trial of AV and VV Optimization) is a multicenter, randomized, crossover, noninferiority trial comparing echocardiographic optimization of atrioventricular (AV) and interventricular delay with a noninvasive blood pressure method.

Prevalence of clinical trial status discrepancies: A cross-sectional study of 10,492 trials registered on both ClinicalTrials.gov and the European Union Clinical Trials Register.

Trial registries are a key source of information for clinicians and researchers. While building OpenTrials, an open database of public trial information, we identified errors and omissions in registries, including discrepancies between descriptions of the same trial in different registries. We set out to ascertain the prevalence of discrepancies in trial completion status using a cohort of trials registered on both the European Union Clinical Trials Register (EUCTR) and ClinicalTrials.gov.

Differences Between Patients Enrolled Early and Late During Clinical Trial Recruitment: Insights From the HF-ACTION Trial.

Changes of attachment characteristics during psychotherapy of patients with social anxiety disorder: Results from the SOPHO-Net trial.

Within a randomized controlled trial contrasting the outcome of manualized cognitive-behavioral (CBT) and short term psychodynamic therapy (PDT) compared to a waiting list condition (the SOPHO-Net trial), we set out to test whether self-reported attachment characteristics change during the treatments and if these changes differ between treatments.

Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial).

Despite the importance of chemotherapy in the treatment of early stage triple negative breast cancer (TNBC), no one optimal regimen has been identified. We conducted a pilot trial comparing outcomes for the three most commonly used chemotherapy regimens to assess the feasibility of conducting a larger definitive trial.


Advertisement
Quick Search
Advertisement
Advertisement